The Market For Micro-Dosing
JR Rahn founder of MindMed will speak about the opportunities for micro-dosing and the opportunities for consumers who want the benefits of psychedelic drugs but without the lengthy time commitment. MindMed’s current non-hallucinogenic compound, 18-MC, isn’t yet classified under the controlled Substances Act and is currently undergoing studies for efficacy. Rahn will talk about the efforts to bring this product to market amid many uncertainties.